Surgeries & Interventions

Contrast Use During PCI on the Decline

New ACC registry data suggests interventional cardiologists are using less contrast for PCI procedures in the cath lab which helps reduce post-PCI acute kidney injury risks, but a deeper look tells us there’s still room for improvement.

  • Iodinated contrast agents are commonly used for PCI with gadolinium-based contrast serving as an alternative but both can cause complications like acute kidney injury.
  • However, the trend is shifting towards minimizing or avoiding contrast use, especially in high-risk patients, through techniques like “zero-contrast” or “ultra-low contrast” PCI.

Searching for cath lab trends, researchers examined 3.12M unique PCI procedures performed by 3.6k physicians from 2018 to 2022 and found that the average contrast volume used during PCI decreased modestly but consistently over the study’s four years.

  • Overall mean PCI contrasts volumes decreased from 168.1 mL in 2018 to 149.8 mL by 2022.
  • Encouragingly, patients at higher preprocedural AKI risk also consistently received less contrast than those at lower risk (160.5 mL vs. 171.3 mL in 2018 down to 143.4 mL vs. 150.4 mL in 2022). 

While the trend is in the right direction, researchers still highlighted that there’s plenty of room for improvement across the board.

  • For example, 37.5% of physicians did not significantly decrease their contrast use during the four years they were followed, while 20% didn’t change volumes at all.
  • When categorized by percent change, 77.1% did not significantly change the amount of contrast they used per procedure.
  • Meanwhile, 1.9% of physicians actually increased their average contrast by >20%.

So what’s the answer? One recent RCT in Canada implemented preprocedural guidelines for safe contrast amounts and showed decreases in both contrast volume and AKI, particularly in higher-risk patients.

  • However, the trial provided feedback at the individual operator level rather than at the site level, so it’s unknown if site-level feedback alone can reduce AKI rates.

The Takeaway

PCI contrast use is headed in the right direction, but there’s still work to be done when it comes to messaging and convincing physicians about reducing volumes during procedures. Whether that’s achieved by more research, a better contrast alternative, or stronger education remains to be seen.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

Cardiology Pharmaceuticals June 16, 2025

No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025

A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures. The sub-analysis examined a total of 920 procedures across 441 patients taking either abelacimab or rivaroxaban, with approximately 1-in-3 patients undergoing an invasive procedure over a median follow-up of 2.1 years. Researchers […]

Like the website? You'll love the newsletter

Completely free. Every Monday and Thursday.

CW Phone Square

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!